China Medical System Holdings Ltd (CMS), a subsidiary of Treasure Sea Ltd, is a pharmaceutical company that markets, promotes and sells pharmaceutical drugs. Its offering product includes plendil, deanxit, xinhuosu, ursofalk, bio flor, combizym, hirudoid, aethoxysklerol, lansoprazole enteric, tacrolimus, cyclosporine, paliperidone, latanoprost, levetiracetam, pons, extendedrelease and doxorubicin hydrochloride liposome, among others. CMS medical aesthetic product comprises vmonalisa, stratamark, mesenteric-mesohyl, and neauvia hyaluronic series. It also offer clinical development services. The company's product pipeline provides various therapeutic fields which include the nervous system, ophthalmology, dermatology, endocrine system, oncology, nephrology, immune system, digestive system and anti-infection. CMS is headquartered in Hong Kong.
Headquarters
Hong Kong
Address
Unit 2106, 21/F, Island Place Tower, 510, , North Point, Hong Kong, Guangdong
Website
web.cms.net.cn/zh/home
Telephone
86 755 82416868
No of Employees
5,701
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
867 (HKG)
Revenue (2022)
$1.1B
-12.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-26.3%
(2022 vs 2021)
Market Cap*
$2.2B
Net Profit Margin (2022)
XYZ
-15.9%
(2022 vs 2021)
* As of and is in US$
China Medical System Holdings Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Complex Generic: | Stratamark |
| Doxorubicin Hydrochloride Liposome Injection | |
| Paliperidone Extended-Release Tablets | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In April, CMS Skinhealth entered into a partnership with Incyte Corp for the advancement and commercialization of povorcitinib. |
| 2024 | Others | In April, the company's New Drug Application was accepted by the National Medical Products Administration of China for Desidustat Tablets. |
| 2024 | Regulatory Approval | In March, the company secured approval from the National Medical Products Administration of the People’s Republic of China to commence a clinical trial of ruxolitinib cream for the treatment of mild to moderate atopic dermatitis. |
Competitor Comparison
| Key Parameters | China Medical System Holdings Ltd | Tasly Pharmaceutical Group Co Ltd | Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd | Hubei Guangji Pharmaceutical Co Ltd | Beijing Beilu Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Hong Kong | China | China | China | China |
| City | Hong Kong | Tianjin | Tianjin | Huanggang | Beijing |
| State/Province | Guangdong | Tianjin | Tianjin | Hubei | Beijing |
| No. of Employees | 5,701 | 9,223 | 4,619 | 1,256 | 923 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Lam Kong | President; Chief Executive; Chairman | Executive Board | 2006 | 58 |
| Chen Yanling | Vice President; Chief Financial Officer; Director | Executive Board | 2006 | 52 |
| Chen Hongbing | Chief Operating Officer; Director; Vice President | Executive Board | 2006 | 56 |
| Wu Sanyan | Secretary; Director - Legal Department | Senior Management | 2009 | 41 |
| Peng Huaizheng | Chief Business Officer | Senior Management | - | 61 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer